NO20034381L - Kombinasjonsdose av cyklooksygenaseinhibitor, en vitamin-D3-omfattende analog og metabolitter derav, og/eller kalsium for forebyggelse avepitelial kreft - Google Patents
Kombinasjonsdose av cyklooksygenaseinhibitor, en vitamin-D3-omfattende analog og metabolitter derav, og/eller kalsium for forebyggelse avepitelial kreftInfo
- Publication number
- NO20034381L NO20034381L NO20034381A NO20034381A NO20034381L NO 20034381 L NO20034381 L NO 20034381L NO 20034381 A NO20034381 A NO 20034381A NO 20034381 A NO20034381 A NO 20034381A NO 20034381 L NO20034381 L NO 20034381L
- Authority
- NO
- Norway
- Prior art keywords
- metabolites
- vitamin
- epithelial cancer
- prevention
- calcium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Det beskrives en fremgangsmåte for å hindre epitelisk cancer så som lunge, prostata eller gynekologisk cancer eller initiering og/eller progresjon av epitelisk cancer så som lunge, prostata eller gynekologisk cancer i et menneske, hvor fremgangsmåten omfatter administrering til mennesket en kombinasjonsdosering av en syklooksygenase (COX) inhibitor, et vitamin D3 inkluderende analoger og metabolitter derav og/eller kalsium. I et ytterligere aspekt vedrører oppfinnelsen en fremgangsmåte for å redusere den effektive dosering av ASA i kjemoforebyggende behandling av eptitelisk cancer i et menneske ved å samadministrere med en ikke toksisk dosering av et vitamin D3 inkluderende analoger og metabolitter derav og/eller Ca i form av en kombinasjonsdosering. I en annen utførelse vedrører oppfinnelsen anvendelse av en syclooksygenase (COX) inhibitor, et vitamin D3 inkluderende analoger og metabolitter derav og/eller kalsium for fremstilling av et medikament for behandling av epitelisk cancer så som lunge, blære, prostata og gynekologisk cancer eller inhiberingen og/eller progresjonen av epitelisk cancer så som lunge, blære, prostata eller gynekologisk cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/825,891 US6703380B2 (en) | 1999-09-29 | 2001-04-05 | Prevention of cancer |
PCT/DK2002/000231 WO2002080889A2 (en) | 2001-04-05 | 2002-04-05 | A combination dosage of a cyclooxygenase (cox) inhibitor, a vitamin d3 including analogues and metabolites thereof and/or calcium for prevention of epithelial cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20034381D0 NO20034381D0 (no) | 2003-10-01 |
NO20034381L true NO20034381L (no) | 2003-12-05 |
Family
ID=25245159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034381A NO20034381L (no) | 2001-04-05 | 2003-10-01 | Kombinasjonsdose av cyklooksygenaseinhibitor, en vitamin-D3-omfattende analog og metabolitter derav, og/eller kalsium for forebyggelse avepitelial kreft |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1389122B1 (no) |
AT (1) | ATE444072T1 (no) |
AU (1) | AU2002338311B2 (no) |
CA (1) | CA2445940C (no) |
DE (1) | DE60233869D1 (no) |
DK (1) | DK1389122T3 (no) |
ES (1) | ES2334215T3 (no) |
IS (1) | IS6976A (no) |
NO (1) | NO20034381L (no) |
NZ (1) | NZ529104A (no) |
PT (1) | PT1389122E (no) |
WO (1) | WO2002080889A2 (no) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI20135701L (fi) * | 2013-06-26 | 2014-12-27 | Mas Metabolic Analytical Services Oy | Farmaseuttisesti käyttökelpoinen ja turvallinen kombinaatio käytettäväksi merkittävien sairauksien hoidossa |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948443A (en) * | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
DK1220676T3 (da) * | 1999-09-29 | 2005-09-05 | Colotech As | Forebyggelse af colorektal cancer |
-
2002
- 2002-04-05 NZ NZ529104A patent/NZ529104A/en unknown
- 2002-04-05 PT PT02759763T patent/PT1389122E/pt unknown
- 2002-04-05 DK DK02759763.2T patent/DK1389122T3/da active
- 2002-04-05 CA CA2445940A patent/CA2445940C/en not_active Expired - Fee Related
- 2002-04-05 EP EP02759763A patent/EP1389122B1/en not_active Expired - Lifetime
- 2002-04-05 AU AU2002338311A patent/AU2002338311B2/en not_active Ceased
- 2002-04-05 AT AT02759763T patent/ATE444072T1/de not_active IP Right Cessation
- 2002-04-05 WO PCT/DK2002/000231 patent/WO2002080889A2/en not_active Application Discontinuation
- 2002-04-05 DE DE60233869T patent/DE60233869D1/de not_active Expired - Lifetime
- 2002-04-05 ES ES02759763T patent/ES2334215T3/es not_active Expired - Lifetime
-
2003
- 2003-10-01 NO NO20034381A patent/NO20034381L/no not_active Application Discontinuation
- 2003-10-03 IS IS6976A patent/IS6976A/is unknown
Also Published As
Publication number | Publication date |
---|---|
NZ529104A (en) | 2004-05-28 |
CA2445940C (en) | 2010-08-24 |
WO2002080889A3 (en) | 2003-02-20 |
DE60233869D1 (de) | 2009-11-12 |
IS6976A (is) | 2003-10-03 |
ES2334215T3 (es) | 2010-03-08 |
PT1389122E (pt) | 2009-12-23 |
EP1389122B1 (en) | 2009-09-30 |
CA2445940A1 (en) | 2002-10-17 |
WO2002080889A2 (en) | 2002-10-17 |
EP1389122A2 (en) | 2004-02-18 |
DK1389122T3 (da) | 2010-02-01 |
NO20034381D0 (no) | 2003-10-01 |
AU2002338311B2 (en) | 2006-08-10 |
ATE444072T1 (de) | 2009-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05011208A (es) | Uso de ivermectina para el tratamiento de desordenes dermatologicos. | |
BR0312573A (pt) | Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina | |
IL154888A (en) | Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid | |
GT200500137A (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis. | |
HUP0202570A1 (hu) | Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk | |
CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
NO20092763L (no) | Isosorbid mononitrat derivater for behandling av tarmlidelser | |
PT1220676E (pt) | Prevencao do cancro colorrectal | |
NO20064753L (no) | Kombinasjonsterapi | |
CL2004002030A1 (es) | Uso de interferon y ribavirina porque sirve para preparar un medicamento para tratar infecciones virales; composicion farmaceutica que comprende interferon, ribavirina y opcionalmente antioxidante; kit y su uso para preparar un medicamento para trata | |
TW200618807A (en) | Prevention and therapeutical agent for hepatitis C virus infection | |
WO2004100893A3 (en) | Methods for treatment of inflammatory diseases using ct-3 or analogs thereof | |
BRPI0519006A2 (pt) | uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos | |
NO20034381L (no) | Kombinasjonsdose av cyklooksygenaseinhibitor, en vitamin-D3-omfattende analog og metabolitter derav, og/eller kalsium for forebyggelse avepitelial kreft | |
BRPI0418801A (pt) | métodos de tratamento, controle ou prevenção de um cáncer especìfico, e de uma doença associada com angiogênese indesejada, de redução ou prevenção de um efeito adverso, composição farmacêutica, e, kit | |
WO2004033484A3 (en) | Use of stable glutamine derivatives to improve drug absorption | |
BRPI0509305A (pt) | uso de um sensibilizador insulìnico, composição farmecêutica, e , kit | |
PT1490049E (pt) | Citalopram para o tratamento da pre3ssao sanguinia elevada. | |
ATE346080T1 (de) | Steroid-verbindungen mit anti-tumoraler wirkung | |
DE10292147D2 (de) | Physiologisch verträgliche Kalium-und Magnesiumsalze enthaltendes pharmazeutisches Präparat sowie dessen Verwendung zur Prophylaxe und/oder Therapie von QT-Zeitverlängerungen | |
CL2004001263A1 (es) | Composicion farmaceutica que comprende lamivudina, estavudina y efavirenzo, o derivados de ellos, kit farmaceutico; procedimiento para su preparacion; y uso en la preparacion de un medicamento para el tratamiento o prevencion de infecciones virales, | |
BRPI0407174A (pt) | Regime de administração para nelfinavir | |
AR043241A1 (es) | Terapia combinada que comprende un derivado de indolpirrol-carbazol y otro agente antitumoral | |
PL1700597T3 (pl) | Kompozycja farmaceutyczna do podawania na skórę, zawierająca łącznie ubidekarenon, despantenol oraz chlorheksydynę lub jej farmakologicznie dopuszczalną sól |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: PLOUGMANN & VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0 |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |